AMRX
Price
$12.18
Change
+$0.18 (+1.50%)
Updated
Dec 3 closing price
Capitalization
3.83B
90 days until earnings call
Intraday BUY SELL Signals
COLL
Price
$47.85
Change
+$0.34 (+0.72%)
Updated
Dec 3 closing price
Capitalization
1.51B
77 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMRX vs COLL

Header iconAMRX vs COLL Comparison
Open Charts AMRX vs COLLBanner chart's image
Amneal Pharmaceuticals
Price$12.18
Change+$0.18 (+1.50%)
Volume$1.63M
Capitalization3.83B
Collegium Pharmaceutical
Price$47.85
Change+$0.34 (+0.72%)
Volume$683.81K
Capitalization1.51B
AMRX vs COLL Comparison Chart in %
AMRX
Daily Signal:
Gain/Loss:
COLL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AMRX vs. COLL commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Hold and COLL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (AMRX: $12.01 vs. COLL: $47.50)
Brand notoriety: AMRX and COLL are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 70% vs. COLL: 58%
Market capitalization -- AMRX: $3.83B vs. COLL: $1.51B
AMRX [@Pharmaceuticals: Generic] is valued at $3.83B. COLL’s [@Pharmaceuticals: Generic] market capitalization is $1.51B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileCOLL’s FA Score has 2 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • COLL’s FA Score: 2 green, 3 red.
According to our system of comparison, COLL is a better buy in the long-term than AMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 4 TA indicator(s) are bullish while COLL’s TA Score has 5 bullish TA indicator(s).

  • AMRX’s TA Score: 4 bullish, 4 bearish.
  • COLL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, COLL is a better buy in the short-term than AMRX.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а -3.50% price change this week, while COLL (@Pharmaceuticals: Generic) price change was +4.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.67%. For the same industry, the average monthly price growth was +0.42%, and the average quarterly price growth was +25.91%.

Reported Earning Dates

AMRX is expected to report earnings on Mar 04, 2026.

COLL is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.67% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRX($3.83B) has a higher market cap than COLL($1.51B). AMRX has higher P/E ratio than COLL: AMRX (1218.00) vs COLL (29.36). COLL YTD gains are higher at: 65.794 vs. AMRX (51.578). AMRX has higher annual earnings (EBITDA): 584M vs. COLL (347M). COLL has more cash in the bank: 222M vs. AMRX (71.5M). COLL has less debt than AMRX: COLL (829M) vs AMRX (2.58B). AMRX has higher revenues than COLL: AMRX (2.85B) vs COLL (707M).
AMRXCOLLAMRX / COLL
Capitalization3.83B1.51B253%
EBITDA584M347M168%
Gain YTD51.57865.79478%
P/E Ratio1218.0029.364,149%
Revenue2.85B707M404%
Total Cash71.5M222M32%
Total Debt2.58B829M311%
FUNDAMENTALS RATINGS
AMRX vs COLL: Fundamental Ratings
AMRX
COLL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
3628
SMR RATING
1..100
9952
PRICE GROWTH RATING
1..100
3837
P/E GROWTH RATING
1..100
127
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COLL's Valuation (66) in the Pharmaceuticals Other industry is somewhat better than the same rating for AMRX (100) in the Pharmaceuticals Major industry. This means that COLL’s stock grew somewhat faster than AMRX’s over the last 12 months.

COLL's Profit vs Risk Rating (28) in the Pharmaceuticals Other industry is in the same range as AMRX (36) in the Pharmaceuticals Major industry. This means that COLL’s stock grew similarly to AMRX’s over the last 12 months.

COLL's SMR Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for AMRX (99) in the Pharmaceuticals Major industry. This means that COLL’s stock grew somewhat faster than AMRX’s over the last 12 months.

COLL's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as AMRX (38) in the Pharmaceuticals Major industry. This means that COLL’s stock grew similarly to AMRX’s over the last 12 months.

COLL's P/E Growth Rating (7) in the Pharmaceuticals Other industry is in the same range as AMRX (12) in the Pharmaceuticals Major industry. This means that COLL’s stock grew similarly to AMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXCOLL
RSI
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 7 days ago
66%
Momentum
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
66%
MACD
ODDS (%)
Bullish Trend 7 days ago
86%
N/A
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
71%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 7 days ago
70%
Declines
ODDS (%)
Bearish Trend 15 days ago
73%
Bearish Trend 15 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 7 days ago
64%
Aroon
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 7 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signal:
Gain/Loss:
COLL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIGKX46.48N/A
N/A
MFS Massachusetts Inv Gr Stk R4
CRIMX24.35N/A
N/A
CRM Mid Cap Value Instl
BRXBX17.19N/A
N/A
MFS Blended Research Intl Eq B
BAFMX17.89N/A
N/A
Brown Advisory Mid-Cap Growth Instl
IOVVX35.22N/A
N/A
Invesco Comstock Select R5

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with VTRS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
-2.48%
VTRS - AMRX
45%
Loosely correlated
+0.09%
TEVA - AMRX
43%
Loosely correlated
+0.62%
AMPH - AMRX
42%
Loosely correlated
-2.91%
PAHC - AMRX
42%
Loosely correlated
-0.10%
BHC - AMRX
39%
Loosely correlated
-2.06%
More

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
+1.37%
AMPH - COLL
43%
Loosely correlated
-2.91%
AMRX - COLL
36%
Loosely correlated
-2.48%
PAHC - COLL
35%
Loosely correlated
-0.10%
VTRS - COLL
34%
Loosely correlated
+0.09%
SNDL - COLL
33%
Loosely correlated
+1.79%
More